Pharmacists concerned about diabetes treatment knowledge
More than three quarters of pharmacists feel they do not know enough about newer treatments for diabetes to perform MURs, a survey has found.
Only 4 per cent and 2 per cent of pharmacists felt they had a thorough understanding of DPP-4 inhibitors and GLP-1 analogues respectively, while 32 per cent were unaware of the latest Nice guidance on the therapies, a survey of 200 pharmacists found.
Natasha Jacques, principal pharmacist for diabetes at Heart of England Foundation Trust, said pharmacists had a key role to play in helping patients get the most out of their medicines.
“It is vital that all pharmacists understand how these new drugs work, and are able to advise patients on how and when to take the drug with the aim of achieving good reductions in blood glucose and HbA1c.”
The survey, conducted in April on behalf of MSD, found nearly two-thirds of pharmacists listed weight gain as the main concern raised by patients with diabetes during consultation, with 44 per cent of pharmacists listing hypoglycaemia as a major concern.
Please note You must be a registered user of Chemist+Druggist and logged in to add comments. Opinions expressed here are those of the writers and do not necessarily reflect those of Chemist+Druggist. Comments are considered in the public domain and may be used in future Chemist+Druggist coverage. We accept no responsibility, legal or otherwise, for the accuracy or the content of member comments. However, any comments deemed to be libellous will be removed
Most popular
- Dispensing errors due to be decriminalised next year
- Accessibility more important than security, says owner of siege pharmacy
- Pharmacy defends against report highlighting unsatisfactory medicines advice
- Nice formalises guidance on analgesics in feverish under-fives
- Plans to include prescribing in pharmacy degree shelved, Senators reveal
